Shanghai Yurui Biotechnology

Shanghai Yurui Biotechnology (Anyang) Pharmaceutical Co., Ltd. is a commercial-stage pharmaceutical manufacturing company based in Anyang, Henan Province, China. Founded in 2005, the company specializes in the production of active pharmaceutical ingredients (APIs) and oral solid dosage forms, including tablets, capsules, and granules. Its product portfolio features a wide range of small molecule drugs such as antazoline hydrochloride (a broad-spectrum anti-arrhythmic and anti-allergic agent), acetylkitasamycin, nifedipine, trimethoprim, and various corticosteroid intermediates like prednisolone phosphate sodium and hydrocortisone sodium phosphate. Operating under strict GMP compliance, the company possesses an annual production capacity of 1,000 tons of bulk drugs and 20 billion units of oral solid formulations, serving both domestic and international markets.